drugset / Trial / NCT00756730
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
Phase 4
Completed
49 enrolled
Community Research Initiative of New England
Tibotec Pharmaceutical Limited · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
For participants with HIV taking either lopinavir or fosamprenavir who have elevated triglycerides, this trial will study the change in triglycerides after switching protease inhibitors.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |